Cargando…

Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites

OBJECTIVE: The efficacy of tolvaptan, an orally active vasopressin V2-receptor antagonist, has recently been reported in patients with massive ascites unresponsive to conventional diuretics. However, the effect of tolvaptan varies among patients. Recently, the prognostic role of the tolvaptan respon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shigefuku, Ryuta, Iwasa, Motoh, Eguchi, Akiko, Tempaku, Mina, Tamai, Yasuyuki, Suzuki, Tatsuya, Takei, Yoshiyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627803/ https://www.ncbi.nlm.nih.gov/pubmed/34719623 http://dx.doi.org/10.2169/internalmedicine.7291-21

Ejemplares similares

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Update on blood‐based biomarkers for chronic liver diseases prognosis: Literature review and institutional experience
por: Iwasa, Motoh, et al.
Publicado: (2021)

Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans
por: Tamai, Yasuyuki, et al.
Publicado: (2022)

Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma
por: Tamai, Yasuyuki, et al.
Publicado: (2020)

Protein Composition of Circulating Extracellular Vesicles Immediately Changed by Particular Short Time of High-Intensity Interval Training Exercise
por: Kobayashi, Yoshinao, et al.
Publicado: (2021)

Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan
por: Iwasa, Motoh, et al.
Publicado: (2019)

A Rare Presentation of Intraperitoneal Ectopic Varices Rupture
por: Shigefuku, Ryuta, et al.
Publicado: (2020)

Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2021)

The prognostic potential of fragmented CK18 serum levels in HCC patients reflecting disease progression and overall hepatocyte damage
por: Eguchi, Akiko, et al.
Publicado: (2022)

Impact of continued administration of tolvaptan on cirrhotic patients with ascites
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
por: Adachi, Takuya, et al.
Publicado: (2021)

Elevation of enterococcus-specific antibodies associated with bacterial translocation is predictive of survival rate in chronic liver disease
por: Iwasa, Motoh, et al.
Publicado: (2022)

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
por: Wang, Shuzhen, et al.
Publicado: (2018)

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients
por: Sugimoto, Ryosuke, et al.
Publicado: (2023)

Serum Liver‐Type Fatty Acid–Binding Protein Is a Possible Prognostic Factor in Human Chronic Liver Diseases From Chronic Hepatitis to Liver Cirrhosis and Hepatocellular Carcinoma
por: Eguchi, Akiko, et al.
Publicado: (2019)

Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites
por: Hosui, Atsushi, et al.
Publicado: (2021)

Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
por: Hirooka, Masashi, et al.
Publicado: (2022)

Complement complex 1 subunit q‐mediated hepatic stellate cell activation with connective tissue growth factor elevation is a prognostic factor for survival in rat and human chronic liver diseases
por: Eguchi, Akiko, et al.
Publicado: (2022)

Development of a New Index to Distinguish Hepatic Encephalopathy through Automated Quantification of Globus Pallidal Signal Intensity Using MRI
por: Tamai, Yasuyuki, et al.
Publicado: (2022)

The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2017)

Neutrophil gelatinase‐associated lipocalin level is a prognostic factor for survival in rat and human chronic liver diseases
por: Yoshikawa, Kyoko, et al.
Publicado: (2017)

A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis
por: Eguchi, Akiko, et al.
Publicado: (2022)

Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab
por: Shigefuku, Ryuta, et al.
Publicado: (2022)

First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan
por: Tsuruya, Kota, et al.
Publicado: (2023)

Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites
por: Arase, Yoshitaka, et al.
Publicado: (2018)

Tolvaptan for the Treatment of Refractory Ascites
por: Kurosaki, Masayuki, et al.
Publicado: (2016)

Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study
por: Shiba, Shunsuke, et al.
Publicado: (2020)

Long-term administration of Tolvaptan to patients with decompensated cirrhosis
por: Kanayama, Kengo, et al.
Publicado: (2020)

Circulating Extracellular Vesicles and Their miR “Barcode” Differentiate Alcohol Drinkers With Liver Injury and Those Without Liver Injury in Severe Trauma Patients
por: Eguchi, Akiko, et al.
Publicado: (2019)

Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial
por: Tang, Jieting, et al.
Publicado: (2020)

Cases with Refractory Ascites and a Delayed Response to Tolvaptan
por: Hagiwara, Satoru, et al.
Publicado: (2016)

Surgical Treatment of Cirrhotic Ascites
Publicado: (1927)

Ayurvedic management of cirrhotic ascites
por: Aswathy, G., et al.
Publicado: (2016)

Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites
por: Huang, Lin-Lin, et al.
Publicado: (2014)

Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model
por: Tanabe, Norikazu, et al.
Publicado: (2017)

Successful endoscopic cyanoacrylate injection therapy for ruptured duodenal varices immediately after balloon‐occluded retrograde transvenous obliteration
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Comment on ‘Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites’
por: Ahmed, Furqan
Publicado: (2017)

A Metabolomic Analysis of Cirrhotic Ascites
por: Beyoğlu, Diren, et al.
Publicado: (2022)

Antiviral Therapy in HCV-infected Decompensated Cirrhotics
por: Danish, Fazal A., et al.
Publicado: (2010)

The Associations between Circulating Bile Acids and the Muscle Volume in Patients with Non-alcoholic Fatty Liver Disease (NAFLD)
por: Kobayashi, Yoshinao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_oaifl96i8eeo4fgahn95dr0be7